These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 9435993)

  • 1. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
    Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors.
    Naranjo CA; Sproule BA; Knoke DM
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S35-47. PubMed ID: 10471171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer antidepressants and the cytochrome P450 system.
    Nemeroff CB; DeVane CL; Pollock BG
    Am J Psychiatry; 1996 Mar; 153(3):311-20. PubMed ID: 8610817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic drug interactions with new psychotropic agents.
    Spina E; Scordo MG; D'Arrigo C
    Fundam Clin Pharmacol; 2003 Oct; 17(5):517-38. PubMed ID: 14703714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in interactions of SSRIs.
    Brøsen K
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the pharmacokinetics of fluvoxamine.
    van Harten J
    Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT; Powers CN; Reinhardt BJ; Weina PJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.